• ExoCoBio

  Participated · Series C · Aug 2020

  ExoCoBio develops exosome-based regenerative aesthetic products and brands. Founded in 2017 and led by CEO Byong Cho, the company has launched ASCE+™, EXOMAGE™, and CELLTWEET™. Those brands target skin rejuvenation, skin immune-modulation, and scalp rejuvenation. The company raised $9.3m in Series C and pre-IPO funding and has cumulatively raised about $56.3m since founding. ExoCoBio has established a strategic alliance with BENEV Company Inc., an FDA-registered medical aesthetic manufacturer in Orange County, California, to support U.S. market activities. The financing is positioned to support continued commercialization of its exosome product lines and near-term growth initiatives. ExoCoBio Inc. is a pharmaceutical R&D and cosmeceutical company developing exosome-based products. The company produces exosome pharmaceuticals and has launched cosmeceutical brands and products such as EXOMAGE™, Celltweet™ and ASCE+™. ExoCoBio works with exosomes—nano-vesicles secreted by cells that contain physiologically active substances and can stimulate cellular or tissue regeneration, with applications in skin and hair. The company plans to use recent funding to set up GMP-compliant exosome manufacturing facilities, hire talent, and secure additional commercialization opportunities in the cosmetics industry. Financially, ExoCoBio raised approximately $26.7M in a Series B and has raised about $46M cumulatively, including an $11M Series A in April 2017. The company was established in January 2017 and is led by CEO Byong Cho.

No current team members are available.